Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

63 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes.
Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. Tomai MA, et al. Cell Immunol. 2000 Jul 10;203(1):55-65. doi: 10.1006/cimm.2000.1673. Cell Immunol. 2000. PMID: 10915562
Metabolically active antigen presenting cells are required for human T cell proliferation in response to the superantigen streptococcal M protein.
Tomai MA, Beachey EH, Majumdar G, Kotb M. Tomai MA, et al. FEMS Microbiol Immunol. 1992 Feb;4(3):155-64. doi: 10.1111/j.1574-6968.1992.tb04982.x. FEMS Microbiol Immunol. 1992. PMID: 1575992
Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica.
Abhyankar MM, Orr MT, Lin S, Suraju MO, Simpson A, Blust M, Pham T, Guderian JA, Tomai MA, Elvecrog J, Pedersen K, Petri WA Jr, Fox CB. Abhyankar MM, et al. Among authors: tomai ma. NPJ Vaccines. 2018 Jun 5;3:22. doi: 10.1038/s41541-018-0060-x. eCollection 2018. NPJ Vaccines. 2018. PMID: 29900011 Free PMC article.
Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.
Abhyankar MM, Noor Z, Tomai MA, Elvecrog J, Fox CB, Petri WA Jr. Abhyankar MM, et al. Among authors: tomai ma. Vaccine. 2017 Feb 7;35(6):916-922. doi: 10.1016/j.vaccine.2016.12.057. Epub 2017 Jan 12. Vaccine. 2017. PMID: 28089548 Free PMC article.
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Vasilakos JP, Tomai MA. Vasilakos JP, et al. Among authors: tomai ma. Expert Rev Vaccines. 2013 Jul;12(7):809-19. doi: 10.1586/14760584.2013.811208. Expert Rev Vaccines. 2013. PMID: 23885825 Review.
Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
Thatcher TH, Luzina I, Fishelevich R, Tomai MA, Miller RL, Gaspari AA. Thatcher TH, et al. Among authors: tomai ma. J Invest Dermatol. 2006 Apr;126(4):821-31. doi: 10.1038/sj.jid.5700167. J Invest Dermatol. 2006. PMID: 16439962
Resiquimod and other immune response modifiers as vaccine adjuvants.
Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP. Tomai MA, et al. Expert Rev Vaccines. 2007 Oct;6(5):835-47. doi: 10.1586/14760584.6.5.835. Expert Rev Vaccines. 2007. PMID: 17931162 Review.
Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
Schölch S, Rauber C, Tietz A, Rahbari NN, Bork U, Schmidt T, Kahlert C, Haberkorn U, Tomai MA, Lipson KE, Carretero R, Weitz J, Koch M, Huber PE. Schölch S, et al. Among authors: tomai ma. Oncotarget. 2015 Mar 10;6(7):4663-76. doi: 10.18632/oncotarget.3081. Oncotarget. 2015. PMID: 25609199 Free PMC article.
TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.
Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP. Inglefield JR, et al. Among authors: tomai ma. J Interferon Cytokine Res. 2008 Apr;28(4):253-63. doi: 10.1089/jir.2007.0097. J Interferon Cytokine Res. 2008. PMID: 18439103
NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.
Dumitru CD, Antonysamy MA, Gorski KS, Johnson DD, Reddy LG, Lutterman JL, Piri MM, Proksch J, McGurran SM, Egging EA, Cochran FR, Lipson KE, Tomai MA, Gullikson GW. Dumitru CD, et al. Among authors: tomai ma. Cancer Immunol Immunother. 2009 Apr;58(4):575-87. doi: 10.1007/s00262-008-0581-7. Epub 2008 Sep 13. Cancer Immunol Immunother. 2009. PMID: 18791716
63 results
Jump to page